<DOC>
	<DOCNO>NCT00247169</DOCNO>
	<brief_summary>The investigator want test whether treatment natural progesterone intravaginally increase cure rate cervical intraepithelial neoplasia grade I II .</brief_summary>
	<brief_title>Vaginal Progesterone Treatment Cervical Dysplasia Grade I II</brief_title>
	<detailed_description>Background : 1 . The development cervical intraepithelial neoplasia ( CIN ) link decreased local immune response evidence decrease Langerhans ' cell ( LC ) count cervical epithelium . Preliminary study show vaginally administer progesterone locally increase number LCs . 2 . There accepted treatment strategy low grade CIN , i.e. , CIN I II , await spontaneous regression . Thus , vaginal progesterone expect increase regression rate cervical dysplasia grade I II . Outcome parameter : Primary outcome parameter : To evaluate whether treatment vaginal progesterone increase regression remission rate CIN I II 6-month treatment period . Secondary outcome parameter : Change immunohistochemically detect expression LCs CIN . Methods : Prospective phase II trial vaginal progesterone treatment CIN I II . 60 patient receive vaginal micronized progesterone 400mg 1x daily 10 days/month menstrual cycle day 16-25 6 month . After 3 6 month patient examine possible regression , persistence , progression disease treat accordingly . Treatment patient progress CIN discontinue 3 month . Follow-up patient ensure base current clinical practice , i.e. , regular outpatient visit every 3 month , lesion completely regress . Diagnosis main inclusion criterion : CIN I II diagnose punch biopsy , lesion fully visible , otherwise healthy subject &lt; 60 year , history breast cancer , patient 's compliance Medication : Micronized progesterone 400mg 1x daily 10 days/month menstrual cycle day 16-25 Duration treatment : 6 month</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>1 . Histological evidence CIN I II 2 . Transformation zone lesion margin fully visible 3 . Compliant subject 4 . Safe contraception 5 . Negative pregnancy test Lesion relate 1 . CIN III , ( micro ) Invasive Cancer 2 . Endocervical lesion , upper margin lesion visible colposcopy 3 . Noncompliance patient 4 . PAP V Drug relate 1 . Age &gt; 60 2 . Hypersensitivity progesterone component formulation 3 . Thrombophlebitis 4 . Undiagnosed vaginal bleeding 5 . Carcinoma breast 6 . Cerebral apoplexy 7 . Severe liver dysfunction 8 . Pregnancy 9 . Depression 10 . Diabetes 11 . Epilepsy 12 . Migraine 13 . Renal dysfunction 14 . Asthma 15 . HIV infection 16 . Hepatitis B C 17 . Concurrent use anticoagulants 18 . Uncontrolled hypertension ( &gt; 160/90 mmHg ) 19 . Breast cancer personal history 20 . Concurrent hormonal therapy include OC Clinical laboratory relate 1 . Hemoglobin &lt; 11 g/dl 2 . Leukocytes &lt; 4,0 x 109/L 3 . Platelet count &lt; 100 x 109/L 4 . Serum bilirubin &gt; 2 x upper cutoff value 5 . Serum GOT &gt; 2 x upper cutoff value 6 . Serum GPT &gt; 2 x upper cutoff value 7 . Serum alkaline phosphatase &gt; 2 x upper cutoff value 8 . Serum creatinine &gt; 2 x cutoff value</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>cervical intraepithelial neoplasia ( CIN )</keyword>
	<keyword>progesterone</keyword>
</DOC>